AUAUniversity播客系列:Episode No. 7

AUA2019 023IC - Chemotherapy And Immunotherapy Options For Genitourinary Malignancies

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

Instructional Course Director(s)
Costas Lallas, MD
Thomas Jefferson University Hospital

Instructional Course Faculty(s)
Anne Calvaresi, DNP, CRNP
Thomas Jefferson University

Edouard Trabulsi, MD, FACS
Sidney Kimmel Medical College at Thomas Jefferson University

泌尿生殖系统恶性肿瘤的化疗和免疫治疗方案综述，包括膀胱、肾、前列腺和睾丸癌。将讨论适应症、结果和毒性以及临床试验概念。生存问题也将是会议的重点，其中将包括简短，直接的教学讲座以及提问和回答时间。标准的护理化疗方案(如MVAC治疗尿路上皮癌)以及较新的免疫治疗方案(如检查点抑制治疗肾细胞癌)将包括在内。会议的目标将包括熟悉这些恶性肿瘤的系统治疗方案，以及他们的具体预期结果和副作用。

Learning Objectives:

• Describe the standard of care chemotherapy regimens for genitourinary malignancies
• Recall both historic and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates.
• Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies.
• Recognize and manage the adverse events related to these agents.
• Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies.
• List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.